Diabetology, Vol. 6, Pages 127: Experience with Oral Semaglutide in Clinical Practice: Efficacy and Safety Data from the Multicentric Croatian Study Diabetology doi: 10.3390/diabetology6110127 Authors:

For many, many years, most of us blindly trusted the pharmaceutical industry to develop drugs that were safe and effective. We didn’t question the food

The reality star began using a GLP-1 in September 2024

Eli Lilly’s LillyDirect platform is partnering with Walmart to let patients pick up prescriptions for its GLP-1 drug Zepbound at Walmart pharmacies, expanding access beyond

Pfizer said Friday it’s suing Novo Nordisk and obesity biotech Metsera, a day after Novo set off a bidding war against Pfizer to acquire Metsera.

Americans enrolled in health insurance plans offered through the Affordable Care Act, commonly known as Obamacare, are expected to rise next year as the debate over

Everyone will die, but we can live healthier, longer lives until that day comes. That’s the guiding principle that motivates the work and advocacy of

Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the

Pop powerhouse Meghan Trainor is showing off a whole new look. While fans can’t stop buzzing about her dramatic transformation, her trainer said the Grammy

by Ingrid Sørdal Følling, Stine Larsen Reigstad, Åsne Ask Hyldmo, Anne-Sofie Helvik Introduction Obesity is a growing health concern and a known risk factor for

Gallup released a survey this week showing that the obesity rate among US adults has fallen to 37% this year, a significant drop from the record high

Since January, one clinic in the UK has started prescribing the weight-loss medication Wegovy to 12-17 year-olds. For some, the results have been life-changing. But

Neuropod cells are a newly discovered type of enteroendocrine cell (EEC) that connect the gut and brain functionally into one circuit. In the mouse colon,

The Zacks Medical – Dental Supplies industry in the Medical sector is entering the final quarter of 2025 with strong momentum and bright prospects for the

The growing use of GLP-1 drugs presents opportunities for food manufacturers but what must NPD teams consider? The post Product puzzle: food makers weigh up

Jonathan Van Ness is responding to the “gigantic conversation” around his decision to use a weight-loss drug after dropping 70 pounds since last year. On

The reality star began using a GLP-1 in September 2024

Eli Lilly dealt a George Foreman-worthy blow in its ongoing heavyweight title bout against Novo Nordisk for weight-loss drugmaker supremacy. The Indianapolis-based pharmaceutical company posted

Mihai Andrei, ZME Science America’s obesity rates have constantly been rising. Over 40% of…

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for type 2 diabetes, now

Medicine is strongly biased towards adopting biochemical models of disease as this facilitates costly therapeutics being developed for each disease and hence sustains the medical

Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9 billion bid for Metsera—more than

The timing of digestion after a meal reveals information essential for evaluating gastrointestinal function and overall digestive health. Alterations in transit time through the GI

The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In

The U.S. obesity rate is declining as more people turn to GLP-1 drugs for weight loss. Bloomberg/Getty Images A new Gallup poll indicates that the

Gallup: After peaking at a record high of 39.9% in 2022, the U.S. adult obesity rate has gradually declined to 37.0% in 2025. This is

The obesity rate in the U.S. is continuing its downward trend. The news comes three years after obesity rates hit a record high. In 2022,

Image source: The Motley Fool. DATE Thursday, October 30, 2025 at 10 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — David A. Ricks

The rate of adult obesity in the United States continued its gradual decline in 2025, as the use of GLP-1 weight loss drugs saw a

For decades, the obesity rate among Americans trended inexorably higher, to a peak of 39.9 percent in 2022. But now, new data from Gallup’s National

AUSTIN, Texas and TOKYO, Oct. 30, 2025 /PRNewswire/ — According to DataM Intelligence, the obesity therapeutics market is on the cusp of major expansion. Although

Drugmaker’s shares jump after revenue from weight-loss drug more than doubles Eli LillyLLY-0.80%decrease; red down pointing triangle reported higher third-quarter profit and raised its full-year

Photo-Illustration: by The Cut; Photos: Getty Images It’s tough to put a dollar amount on the advantages of looking conventionally “attractive” (young, well-dressed, thin), but

PITTSBURGH, Pa., Oct. 30, 2025 /PRNewswire/ — GNC, the global leader in health and wellness, announced the publication of a new peer-reviewed journal article, “Dietary

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly.  Lilly’s

Obesity levels in the US are falling, driven by the increased use of GLP-1 weight-loss drugs such as Ozempic. The US has some of the

A bidding war has broken into the open for obesity-focused Metsera, with Novo Nordisk on Thursday saying it had made an offer for the biotech,